StockData
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc. (CBIO) stock

CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$13.04−0.46 (-3.41%)

Close on Nov 17, 2026Market cap $484.36MP/E –Yield –

Crescent Biopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Crescent Biopharma's revenue for the twelve months ending Dec 31, 2022 was $75.00K, down 93.5% year over year. For fiscal 2025 it was $10.84M, up 108340.0% from the year before. The highest annual figure on record is $20.07M in fiscal 2015.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.84M+108340.0%
FY2023Dec 31, 2023$10.00K-86.7%
FY2022Dec 31, 2022$75.00K-93.5%
FY2021Dec 31, 2021$1.16M-88.6%
FY2020Dec 31, 2020$10.16M+54834.8%
FY2016Dec 31, 2016$18.50K-99.9%
FY2015Dec 31, 2015$20.07M+33.6%
FY2014Dec 31, 2014$15.03M+276.4%
FY2013Dec 31, 2013$3.99M-73.8%
FY2012Dec 31, 2012$15.26M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$1.04M–
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$75.00K-92.9%
Q4 FY2021Dec 31, 2021$17.63K-89.2%
Q3 FY2021Sep 30, 2021$86.56K-91.3%
Q2 FY2021Jun 30, 2021$142–
Q1 FY2021Mar 31, 2021$1.06M-88.3%
Q4 FY2020Dec 31, 2020$162.94K–
Q3 FY2020Sep 30, 2020$1.00M+5305.4%
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$9.00M–
Q4 FY2016Dec 31, 2016$0–
Q3 FY2016Sep 30, 2016$18.50K–

More Crescent Biopharma figures

See a number that looks wrong?